TSLA
Tesla
-- 454.130 NVDA
NVIDIA
-- 139.930 RGTI
Rigetti Computing
-- 15.4400 LAES
SEALSQ Corp
-- 8.760 PLTR
Palantir
-- 82.140 
NEWS
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
Nuvectis Pharma (NASDAQ: NVCT) has announced that its drug NXP800 has received Orphan Drug Designation from the FDA for treating ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers. This designation is significant as ovarian cancer typically exceeds the 200,000 patient threshold for Orphan Drug eligibility. The company views this as validation for NXP800's mechanism of action and target patient population in their ongoing Phase 1b clinical trial for platinum-resistant, ARID1a-mutated ovarian cancer. Nuvectis plans to provide a data update from this study in fall 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment